Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics
What Is the Forecasted Market Size of the Immune Thrombocytopenia Market by 2029?
The immune thrombocytopenia market size has grown strongly in recent years. It will grow from $3.43 billion in 2024 to $3.61 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to increasing prevalence of autoimmune disorders, rise in incidence of chronic liver diseases, increasing penetration of healthcare services, expansion of healthcare infrastructure, and rising government support.
The immune thrombocytopenia market size is expected to see strong growth in the next few years. It will grow to " $4.48 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to rising prevalence of thrombocytopenia, rising healthcare expenditure, expansion of therapies, rising prevalence of blood disorders, and growing aging population. Major trends in the forecast period include technological advancements in diagnostics, integration of digital health solutions, shift towards combination therapies, telemedicine adoption, and integration of artificial intelligence in diagnostics.
Get your free report sample today:
What Are the Significant Market Forces Driving the Immune Thrombocytopenia Market Performance?
The growing prevalence of autoimmune diseases is expected to propel the growth of the immune thrombocytopenia market going forward. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy cells and tissues, treating them as foreign threats. This abnormal response leads to inflammation and damage in various organs and systems. The rise in autoimmune diseases is linked to genetic predispositions, environmental factors, lifestyle changes, and increasing awareness leading to better diagnosis. Autoimmune diseases cause immune thrombocytopenia by triggering the immune system to attack and destroy the body's platelets or impair their production in the bone marrow. For instance, in November 2024, according to the Versorgungsatlas.de, a Germany-based organization, in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61%. Therefore, the growing prevalence of autoimmune diseases is driving the growth of the immune thrombocytopenia market.
What Are the Primary Market Segments in the Immune Thrombocytopenia Market?
The immune thrombocytopeniamarket covered in this report is segmented –
1) By Type: Primary Immune Thrombocytopenia; Secondary Immune Thrombocytopenia; Acquired Immune Thrombocytopenia
2) By Treatment Type: Intravenous Immunoglobulin; Thrombopoietin Receptor Agonists; Immunosuppressive Therapy
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Primary Immune Thrombocytopenia: Acute Primary ITP; Chronic Primary ITP; Persistent Primary ITP
2) By Secondary Immune Thrombocytopenia: Drug-Induced ITP; Infection-Associated ITP; Autoimmune Disorder-Related ITP
3) By Acquired Immune Thrombocytopenia: Immune-Mediated Acquired ITP; Non-Immune Acquired ITP
Which Future-Ready Trends Are Expected to Influence the Immune Thrombocytopenia Market?
Major companies operating in the immune thrombocytopenia market are prioritizing therapeutic advancements, particularly in intravenous therapy, to enhance treatment effectiveness, accelerate response times, improve patient adherence, and address unmet medical needs in thrombocytopenia management. Intravenous (IV) therapy is a medical treatment that involves delivering fluids, medications, or nutrients directly into a patient's vein through an IV line. For instance, in March 2024, Argenx SE, a Netherlands-based biotechnology company, announced that the Japan Ministry of Health, Labor, and Welfare (MHLW) had approved VYVGART for intravenous administration in adults with primary immune thrombocytopenia (ITP). This approval represents a major advancement in treatment options, offering a targeted approach with rapid effectiveness and sustained platelet response, addressing critical unmet needs in autoimmune disease management.
Who Are the Established and Emerging Companies Competing in the Immune Thrombocytopenia Market?
Major companies operating in the immune thrombocytopenia market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Novartis AG, Amgen Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Intas Pharmaceuticals Ltd., CSL Behring, Griffols, UCB Pharma, Kyowa Kirin, Sobi (Swedish Orphan Biovitrum), 3SBio Inc., Biotest AG, Shionogi & Co. Ltd., Ligand Pharmaceuticals, Rigel Pharmaceuticals, Symphogen, Hansa Biopharma, Argenx.
Get the detailed immune thrombocytopenia market report today
Which Region Is Expected to Dominate the Immune Thrombocytopenia Market During the Forecast Period?
North America was the largest region in the immune thrombocytopenia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immune thrombocytopenia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment